drug

ALLO-316

1 story · latest Nov 3, 2026

Follow ALLO-316. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Allogene Therapeutics

Timeline

IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issues

Nov 3Quarterly updateAlector, Inc.Allogene Therapeutics

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.